AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 5th, 2020 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Registration Rights Agreement (this “Agreement”) is made and entered into as of February 4, 2020, between Aimmune Therapeutics, Inc., a Delaware corporation (the “Company”), and Nestle Health Science US Holdings, Inc., a Delaware corporation (the “Purchaser”).
Nestle Health Science US Holdings, Inc. Stamford, CT 06902Standstill Agreement • February 5th, 2020 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
In connection with the acquisition of Common Stock, par value $0.0001 per share (the “Common Stock”), and Series A Preferred Stock, par value $0.0001 per share (the “Series A Preferred Stock”) of Aimmune Therapeutics, Inc., a Delaware corporation (the “Company”), by Nestle Health Science US Holdings, Inc., a Delaware corporation (the “Purchaser”), pursuant to the Securities Purchase Agreement, dated as of February 4, 2020, between the Company and the Purchaser (the “Purchase Agreement”), the Company and the Purchaser desire to amend and restate that certain amended and restated standstill agreement, dated November 11, 2018 (the “Prior Agreement”) to accept the rights and covenants hereof in lieu of their rights and covenants in the Prior Agreement. In connection therewith, the Purchaser hereby delivers this amended and restated standstill agreement (this “Standstill Agreement”) to the Company in accordance with the terms of the Purchase Agreement. Capitalized terms used but not otherwi
AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT between SOCIÉTÉ DES PRODUITS NESTLÉ S.A. and AIMMUNE THERAPEUTICS, INC.Strategic Collaboration Agreement • February 5th, 2020 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT (this “Agreement”) is made as of February 4, 2020 (the “Effective Date”), by and between Société des Produits Nestlé S.A., a company organized and existing under the laws of Switzerland and the successor to Nestec Ltd., having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”), and Aimmune Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005, USA (“Aimmune”). NHSc and Aimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AIMMUNE THERAPEUTICS, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 5th, 2020 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED STRATEGIC COLLABORATION AGREEMENT (this “Agreement”) is made as of February 4, 2020 (the “Effective Date”), by and between Société des Produits Nestlé S.A., a company organized and existing under the laws of Switzerland and the successor to Nestec Ltd., having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”), and Aimmune Therapeutics, Inc., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 8000 Marina Boulevard, Suite 300, Brisbane, CA 94005, USA (“Aimmune”). NHSc and Aimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF FEBRUARY 4, 2020 BY AND BETWEEN XENCOR, INC. AND AIMMUNE THERAPEUTICS, INC.License, Development and Commercialization Agreement • February 5th, 2020 • Aimmune Therapeutics, Inc. • Pharmaceutical preparations • California
This License, Development and Commercialization Agreement (this “Agreement”), dated as of February 4, 2020 (the “Effective Date”), is made by and between Xencor, Inc. (“Xencor”), and Aimmune Therapeutics, Inc. (“Aimmune”). Xencor and Aimmune are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
